Stocktwits on MSN
CVM stock sinks in pre-market trading after announcing second equity raise for its cancer drug in just over a month
The biotech firm said it intends to use the gross proceeds for the development of its Multikine cancer drug, which has an Orphan Drug Designation in the U.S. ・This comes after Cel-Sci announced an ...
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy. 9 Out of the Last 10 Summers this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results